论文部分内容阅读
目的探讨紫杉醇联合卡铂治疗晚期非小细胞肺癌的临床疗效。方法将2006年2月至2011年12月收治的110例晚期非小细胞肺癌患者随机分为两组,对照组给予顺铂单药化疗,治疗组采用紫杉醇联合卡铂化疗,比较两种治疗方案的临床总有效率及不良反应。结果治疗组临床总有效率为89.1%,对照组为74.5%,差异有统计学意义(P<0.05)。两组患者的主要不良反应为恶心、呕吐、白细胞减少、血小板减少和血红蛋白减少,且两组患者Ⅰ~Ⅱ级发生率基本相当,差异无统计学意义(P>0.05)。结论与单用顺铂相比,紫杉醇联合卡铂治疗晚期非小细胞肺癌临床疗效显著,且未明显增加不良反应,值得临床推广应用。
Objective To investigate the clinical efficacy of paclitaxel combined with carboplatin in the treatment of advanced non-small cell lung cancer. Methods One hundred and ten patients with advanced non-small cell lung cancer who were admitted between February 2006 and December 2011 were randomly divided into two groups. The control group was treated with cisplatin alone. The treatment group was treated with paclitaxel combined with carboplatin. The two treatment plans were compared The total clinical effective rate and adverse reactions. Results The total clinical effective rate was 89.1% in the treatment group and 74.5% in the control group, the difference was statistically significant (P <0.05). The main adverse reactions were nausea, vomiting, leukopenia, thrombocytopenia and hemoglobin in both groups. The incidence of grade Ⅰ ~ Ⅱ was similar between the two groups, with no significant difference (P> 0.05). Conclusion Compared with cisplatin alone, paclitaxel combined with carboplatin in the treatment of advanced non-small cell lung cancer has a significant clinical effect, and no significant increase in adverse reactions, is worthy of clinical application.